Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated ...

French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical ...

Icotrokinra Improves Plaque Psoriasis Affecting High-Impact Areas. June 13, 2025. Upadacitinib Reduces Pain and Improves Outcomes in Axial Spondyloarthritis. June 13, 2025. CTD-ILD Burden Highest ...

Let's just maybe stay within that and talk a little bit about the oral IL-23, Icotrokinra. Tom Cavanaugh. It's a test. Asad Haider. It's all of the test.

BARCELONA - Johnson & Johnson’s (NYSE:JNJ) Tremfya demonstrated significant ability to inhibit joint structural damage progression in patients with active psoriatic arthritis compared to placebo, ...

Icotrokinra (Johnson & Johnson) Interleukin-23 receptor blocker: Treatment of scalp and genital psoriasis. Phase 3 results: Endocrine Disorders: Somapacitan (Novo Nordisk) Human growth hormone analog: ...